Get the Stockscreener App
13.78
4.97%
-0.72
After Hours:
14.60
0.82
+5.95%
Adaptive Biotechnologies Corp stock is traded at $13.78, with a volume of 3.17M.
It is down -4.97% in the last 24 hours and down -6.95% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$14.50
Open:
$14.74
24h Volume:
3.17M
Relative Volume:
1.64
Market Cap:
$2.20B
Revenue:
$276.98M
Net Income/Loss:
$-59.46M
P/E Ratio:
-34.56
EPS:
-0.3987
Net Cash Flow:
$-48.95M
1W Performance:
-1.85%
1M Performance:
-6.95%
6M Performance:
-21.66%
1Y Performance:
+37.39%
1-Day Range:
$13.64
$14.83
1-Week Range:
$13.22
$14.83
52-Week Range:
$8.375
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
13.78 | 2.32B | 276.98M | -59.46M | -48.95M | -0.3987 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised - Investing.com
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call - Benzinga
Adaptive Biotechnologies: Q1 Earnings Snapshot - marketscreener.com
[10-Q] Adaptive Biotechnologies Corp Quarterly Earnings Report - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) lifts 2026 MRD outlook after 35% Q1 revenue growth - Stock Titan
Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain - Stock Titan
Adaptive Biotechnologies earnings on deck after 55% revenue surge - Investing.com
MSN Money - MSN
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares - Investing.com
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions - Yahoo Finance
Adaptive Biotechnologies Corp (HAM:1HM) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Adaptive Biotechnologies Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Valuation: Significantly Overvalued - GuruFocus
Adaptive Biotechnologies Corp Stock Intrinsic Values | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Historical Valuations | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Operating Data - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Adaptive Biotechnologies Corp Stock Baskets | HAM:1HM - GuruFocus
Who's Buying or Selling Adaptive Biotechnologies Corp (HAM:1HM) Stock Today? - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM)Valuation Measures & Financial Statistics - GuruFocus
Adaptive Biotechnologies Corp Stock Warning Signs - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) DCF Valuation - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock Earnings Transcripts - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock Price, Trades & News - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Dividend - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock Price & 30 Year Financial Data - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock News, Headlines & Updates - GuruFocus
Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock By Investing.com - Investing.com India
Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock - Investing.com
Adaptive Biotechnologies (ADPT) exec trades shares under Rule 10b5-1 plan - Stock Titan
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means - AOL.com
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock By Investing.com - Investing.com Australia
Time To Buy? Stock Analysis: NIO, XPeng XPEV, Costco, Adaptive Biotechnologies ADPT, GE (JtamyA8uVU) - Fathom Journal
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock - Investing.com
Adaptive Biotechnologies (ADPT) president sells 57K shares, exercises options - Stock Titan
[ARS] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) 2026 proxy details and 2025 performance - Stock Titan
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock By Investing.com - Investing.com India
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock - Investing.com
Adaptive Biotechnologies (ADPT) COO sells shares, exercises options under 10b5-1 plan - Stock Titan
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? - AOL.com
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies - Intellectia AI
Adaptive Biotechnologies: Strong Sequencing, Weak Margin Of Safety (NASDAQ:ADPT) - Seeking Alpha
Is Adaptive Bio (ADPT) stock stronger than peers (Investor Interest) 2026-04-18Investment Signal Network - Cổng thông tin điện tử tỉnh Lào Cai
Adaptive Biotechnologies Hits Day Low of $13.37 Amid Price Pressure - Markets Mojo
Adaptive Biotechnologies president Rubinstein sells $826k in ADPT stock By Investing.com - Investing.com UK
Adaptive Biotechnologies president Rubinstein sells $826k in ADPT stock - Investing.com
Adaptive Biotechnologies (ADPT) COO exercises options and sells 57,180 shares - Stock Titan
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 - The Manila Times
Adaptive Biotechnologies schedules May 5 webcast for Q1 2026 results - Stock Titan
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):